Millennium Management LLC Buys New Shares in Liquidia Co. (NASDAQ:LQDA)

Millennium Management LLC bought a new stake in Liquidia Co. (NASDAQ:LQDA) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 44,753 shares of the company’s stock, valued at approximately $526,000. Millennium Management LLC owned approximately 0.05% of Liquidia at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Liquidia by 14.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,981 shares of the company’s stock valued at $423,000 after buying an additional 4,415 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Liquidia by 1,484.5% in the fourth quarter. Janus Henderson Group PLC now owns 535,552 shares of the company’s stock valued at $6,293,000 after buying an additional 501,752 shares in the last quarter. Focus Partners Wealth grew its stake in shares of Liquidia by 20.7% in the fourth quarter. Focus Partners Wealth now owns 90,500 shares of the company’s stock valued at $1,064,000 after buying an additional 15,500 shares in the last quarter. D. E. Shaw & Co. Inc. bought a new position in shares of Liquidia in the fourth quarter valued at $142,000. Finally, Deutsche Bank AG grew its stake in shares of Liquidia by 53.4% in the fourth quarter. Deutsche Bank AG now owns 51,075 shares of the company’s stock valued at $601,000 after buying an additional 17,790 shares in the last quarter. 64.54% of the stock is owned by institutional investors.

Liquidia Stock Performance

Shares of Liquidia stock opened at $18.14 on Monday. The firm has a 50-day moving average of $14.97 and a 200-day moving average of $14.03. The stock has a market cap of $1.55 billion, a PE ratio of -11.13 and a beta of 0.04. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $19.41.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). The business had revenue of $3.12 million during the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. Equities research analysts predict that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on LQDA. Needham & Company LLC reissued a “buy” rating on shares of Liquidia in a research note on Monday, June 2nd. Oppenheimer set a $13.00 price objective on shares of Liquidia and gave the stock an “underperform” rating in a research report on Monday, May 19th. Scotiabank lifted their price objective on shares of Liquidia from $36.00 to $37.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, May 28th. Raymond James lifted their price objective on shares of Liquidia from $27.00 to $29.00 and gave the stock a “strong-buy” rating in a research report on Friday, May 9th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Liquidia in a research report on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Liquidia presently has an average rating of “Moderate Buy” and an average price target of $26.67.

Insider Activity at Liquidia

In related news, General Counsel Russell Schundler sold 5,964 shares of the business’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $80,931.48. Following the completion of the transaction, the general counsel now owns 570,301 shares of the company’s stock, valued at $7,738,984.57. The trade was a 1.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Rajeev Saggar sold 2,450 shares of the business’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the transaction, the insider now directly owns 263,152 shares of the company’s stock, valued at approximately $3,597,287.84. The trade was a 0.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock valued at $450,233 over the last quarter. 26.50% of the stock is owned by corporate insiders.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).